Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 12/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21957013 | 0.87 | HASPIN (0.44) | HASPINMAPTGABRA5DAO | |
| SCHEMBL22502909 | 0.79 | MAPT (0.46) | HASPINMAPTTOP2ACYP19A1KCNH2 | |
| SCHEMBL24312244 | 0.79 | MAPT (0.41) | MAPTGABRA5DAONAMPTTOP2A | |
| SCHEMBL22016213 | 0.78 | MAPT (0.40) | HASPINMAPTGABRA5DAONAMPT | |
| SCHEMBL21955107 | 0.75 | DAO (0.62) | MAPTDAO | |
| SCHEMBL31039545 | 0.75 | DAO (0.62) | MAPTDAO | |
| SCHEMBL35211579 | 0.75 | KDM4E (0.48) | HASPINMAPTDAONAMPTTOP2A | |
| SCHEMBL10151406 | 0.73 | MAPT (0.47) | HASPINMAPTNAMPTTOP2ACYP19A1 | |
| SCHEMBL22016175 | 0.73 | AAK1 (0.38) | MAPTGABRA5NAMPTTOP2AQRFPR | |
| SCHEMBL8268970 | 0.72 | BRPF1 (0.55) | MAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | HASPIN 2648/4885MAPT 2929/4885GABRA5 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.